"Diabetes in Germany" (DIG) study - A prospective 4-year-follow-up study on the quality of risk factor control in patients with type 2 diabetes in daily practice;"Diabetes in Germany" (DIG)-studie - Prospektive 4-jahres-studie zur therapiequalität bei typ-2-diabetes in der praxis

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 7, 2009, Pages 291-297

  Ott, Petra ^a   Benke, I ^b   Stelzer, J ^b   Kohler C ^b   Hanefeld, M ^b  

^a Interdisciplinary Diabetic Foot Unit   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Diabetes type 2; Hypertension; Multifactorial intervention; Risk factor control; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DIABETIC DIET; FOLLOW UP; GERMANY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PROSPECTIVE STUDY; RISK FACTOR; BLOOD; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; FEMALE; HEALTH CARE QUALITY; MALE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; RISK FACTORS;

EID: 60549090902     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0028-1123994     Document Type: Article

References (51)

1. Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab 2008 [Epub ahead of print]
2. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 12;358: 2545-2559
3. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 12;358: 2560-2572 (Pubitemid 351831357)
4. Angaben des Bundesamtes für Statistik (Wiesbaden) 2006
5. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86 (Pubitemid 34073138)
6. Bierwirth RA, Kron P, Lippmann-Grob B et al. Die TEMPO-Studie: Kostenanalyse in der diabetologischen Schwerpunktpraxis und Definition diabetesspezifischer Risikoprofile. Diab Stoffw 2003; 12: 83-94 (Pubitemid 36427205)
7. Brown LC, Johnson JA, Majumdar SR et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004; 171;9: 1189-1192 (Pubitemid 39518012)
8. Bruno G, Merletti F, Biggeri A et al. Metabolic syndrome as a predictor of allcause and cardiovascular mortality in type 2 diabetes - the Casale- Monferrato-Study. Diab Care 2004; 27: 2689-2694 (Pubitemid 39441471)
9. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 2004; 364: 685-696 (Pubitemid 39140624)
10. Comaschi M, Coscelli C, Cucinotta D et al. SFIDA Study Group - Italian Association of Diabetologists (AMD). Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: the SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. Nutr Metab Cardiovasc Dis 2005; 15: 204-211
11. De Berardis G, Pellegrini F, Franciosi M et al. QuED Study: Quality of care and outcomes in type 2 diabetic patients: a comparison between general practice and diabetes clinics. Diabetes Care 2004; 27;2: 398-406 (Pubitemid 38174064)
12. Deutscher Gesundheitsbericht 2008; Diabetes Deutsche Diabetes-Union (DDU) Kirchheimverlag,
13. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 7;358: 580-591 (Pubitemid 351214285)
14. GæP , Vedel P, Larsen N. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003; 348;5: 383-393
15. Goderis G, Boland B. Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments. Acta Clin Belg 2004; 59/6: 329-339 (Pubitemid 40395402)
16. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: rates of medical regimen change. Diabetes Care 2005; 28: 337-442 (Pubitemid 40170936)
17. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39;12: 1577-1583 (Pubitemid 26397370)
18. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997; 14; 3: 6-11
19. Hanefeld M, Koehler C, Gallo S et al. Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovascular Diabetology 2007; 6: 6-13 (Pubitemid 46813283)
20. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin- convertingenzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616 (Pubitemid 29087980)
21. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762 (Pubitemid 28269185)
22. Hauner H, Köster I, Ferber L von. Prävalenz des Diabetes mellitus in Deutschland 1998-2001 - Sekundärdatenanalyse einer Versichertenstichprobe der AOK Hessen/KV Hessen. Dtsch Med Wochenschr 2003; 128: 2632-2638
23. Hauner H. Epidemiologie und Kostenaspekte des Diabetes in Deutschland. Dtsch Med Wochenschr 2005; 130: S64-S65
24. Hauner H, Köster I, Ferber L von. Ambulante Versorgung von Patienten mit Diabetes mellitus im Jahr 2001. Dtsch Med Wochenschr 2003; 128: 2638-2643
25. Heart Outcomes Prevention Evalution (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259 (Pubitemid 30068516)
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol-Lowering with Simvastatin in 5963 People with Diabetes: a Randomised Placebo-Controlled Trial. Lancet 2003; 361: 2005-2026
27. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
28. Janka HU, Dirschedl P. Systolic blood pressure as a predictor for cardiovascular disease in diabetes. A 5-year longitudinal study. Hypertension 1985; 7: 1190-1194
29. Johnson ML, Pietz K, Battleman DS, Beyth RJ. Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care 2006; 44: 39-46
30. Koehler C, Ott P, Benke I, Hanefeld M the DIG Study Group. Comparison of the Prevalence of the Metabolic Syndrome by WHO, AHA/NHLBI, and IDF Definitions in a German Population with Type 2 Diabetes: The Diabetes in Germany (DIG) Study. Horm Metab Res 2007; 39 (9): 632-635
31. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. CODE-2 Advisory Board Diabetologia 2002; 45: 23-28 (Pubitemid 34762211)
32. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE)): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010 (Pubitemid 34286537)
33. Orozco-Beltrán D, Gil-Guillen VF, Quirce F Collaborative Diabetes Study Investigators. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract 2007; 61: 909-915 (Pubitemid 46745231)
34. Ott P, Benke I, Köhler C, Hanefeld M die DIG-Studiengruppe. Qualität der Therapie des Metabolischen Syndroms sowie der Hypercholesterolämie bei Patienten mit Typ-2-Diabetes ohne und mit Makroangiopathie: Die DIG (Diabetes in Germany)-Studie. Diab Stoffwechsel und Herz 2006; 1: 9-18
35. Ott P, Benke I, Köhler C, Hanefeld M. Praxis der Insulintherapie bei Typ 2 Diabetikern im Rahmen der DIG-(Diabetes in Germany) Studie. Diabetologie 2006; 1: 366-373
36. Ott P, Köhler C, Hanefeld M. Grunddaten der "Diabetes in Deutschland"- Studie (DIG). Prospektive 4-Jahres-Studie zur Epidemiologie des Typ-2- Diabetes in Deutschland. Der Diabetologe 2006; Suppl 1: 44-48
37. Parving HH, Lehnert H, Brochner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
38. Rosenson RS, Reasner CA. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Curr Opin Cardiol 2004; 19;5: 480-487 (Pubitemid 39222965)
39. Sämann A, Kaiser J, Seeliger S, Müller UA. Ergebnisse der Diabetes-Karte Thüringen 2003 - Ein Projekt zur kontinuierlichen Evaluierung und Optimierung der Behandlungsqualität in der primären Versorgung von Patienten mit Diabetes mellitus. Diab Stoffw 2004; 13: 287-294
40. Scherbaum WA, Landgraf R. Praxis-Leitlinien der deutschen Diabetes- Gesellschaft (DDG). Diabetologie 2006; 11 [Suppl 2]: 237-242
41. Schulze J, Rothe U, Muller G, Kunath H. Fachkommission Diabetes Sachsen: Verbesserung der Versorgung von Diabetikern durch das sächsische Betreuungsmodell. Dtsch Med Wochenschr 2003; 23: 1161-1166
42. UKPDS Group. (UKPDS 34): prospective observational study. Lancet 1998; 352: 854-856
43. Supina AL, Guirguis LM, Majumdar SR et al. Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus. Clin Ther 2004; 26: 598-606 (Pubitemid 38586461)
44. Tuomilehto J, Rastenyte D, Birkenhager WH et al. Effects of calciumchannel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677-684
45. Tuomilehto J, Rastenyte D, Jousilahti P et al. Diabetes mellitus as a risk factor for death from heart stroke. Prospective study of the middleaged Finnish population. Stroke 1997; 27: 210-215
46. Turner RC, Millns H, Neil HAW et al, UKPDS Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ 1998; 316: 823-
47. U.K. Prospective Diabetes Study (UKPDS) Group 8. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes; UKPDS 38. Brit Med J 1998; 320: 837-853
48. Wan Q, Taggart J, Harris MF et al. Investigation of cardiovascular risk factors in type 2 diabetes in a rural Australian Division of General Practice. Med J Aust 2008; 21;189 (2): 86-89
49. Welch V, Tang SS. Treatment and control of BP and lipids in patients with hypertension and additional risk factors. Am J Cardiovasc Drugs 2007; 7 (5): 381-389 (Pubitemid 47624542)
50. West KM, Ahuja MM, Bennett PH et al. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983; 6: 361-369
51. Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther 2007; 29: 316-325 (Pubitemid 46661861)